$0.87
2.22%
Nasdaq, Sep 02, 10:15 pm CET
ISIN
US69012T2069
Symbol
OTLK

Outlook Therapeutics, Inc. Stock price

$0.87
-1.14 56.71% 1M
-0.55 38.73% 6M
-1.02 53.96% YTD
-6.48 88.16% 1Y
-20.93 96.01% 3Y
-12.15 93.32% 5Y
-682.33 99.87% 10Y
-682.33 99.87% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.02 2.22%
ISIN
US69012T2069
Symbol
OTLK
Industry

Key metrics

Basic
Market capitalization
$38.7m
Enterprise Value
$64.2m
Net debt
$25.5m
Cash
$8.9m
Shares outstanding
43.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
25.6 | 6.4
EV/Sales
42.5 | 10.6
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-251.7%
Return on Equity
102.7%
ROCE
798.1%
ROIC
-6,787.8%
Debt/Equity
-0.9
Financials (TTM | estimate)
Revenue
$1.5m | $6.0m
EBITDA
$-72.5m | -
EBIT
$-72.6m | $-56.1m
Net Income
$-43.4m | $-74.5m
Free Cash Flow
$-56.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-17.7% | -
EBIT
-17.7% | 22.1%
Net Income
54.0% | 0.7%
Free Cash Flow
13.1%
Margin (TTM | estimate)
Gross
70.8%
EBITDA
-4,817.2% | -
EBIT
-4,824.6%
Net
-2,885.9% | -1,234.2%
Free Cash Flow
-3,736.5%
More
EPS
$-1.2
FCF per Share
$-1.3
Short interest
8.0%
Employees
23
Rev per Employee
$0.0
Show more

Is Outlook Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Outlook Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Outlook Therapeutics, Inc. forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Outlook Therapeutics, Inc. forecast:

Buy
82%
Hold
18%

Financial data from Outlook Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1.51 1.51
-
100%
- Direct Costs 0.44 0.44
-
29%
1.07 1.07
-
71%
- Selling and Administrative Expenses 40 40
47% 47%
2,647%
- Research and Development Expense 34 34
1% 1%
2,233%
-73 -73
18% 18%
-4,802%
- Depreciation and Amortization 0.11 0.11
10% 10%
7%
EBIT (Operating Income) EBIT -73 -73
18% 18%
-4,810%
Net Profit -43 -43
54% 54%
-2,877%

In millions USD.

Don't miss a Thing! We will send you all news about Outlook Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Outlook Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
44 minutes ago
ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the EURETINA Innovation Spotlight being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris.
Neutral
GlobeNewsWire
one day ago
ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 ...
Negative
Invezz
6 days ago
Shares of Outlook Therapeutics fell sharply on Thursday after the US Food and Drug Administration (FDA) rejected the company's application for its experimental eye drug ONS-5010, a proposed treatment for wet age-related macular degeneration (wet AMD).
More Outlook Therapeutics, Inc. News

Company Profile

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Cranbury, NJ.

Head office United States
CEO Lawrence Kenyon
Employees 23
Founded 2010
Website outlooktherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today